Meeder Asset Management Inc Anavex Life Sciences Corp. Transaction History

Meeder Asset Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$16.88 - $23.31 $9,115 - $12,587	-540 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$10.16 - $28.86 $5,486 - $15,584	540 New	540 $12,000
Q2 2020 Aug 11, 2020	SELL	$2.62 - $5.2 $4,139 - $8,216	-1,580 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.38 - $5.81 $3,729 - $9,104	1,567 Added 12053.85%	1,580 $4,000
Q4 2019 Feb 13, 2020	BUY	$2.31 - $3.14 $30 - $40	13 New	13 $0
Q3 2019 Oct 17, 2019	SELL	$2.22 - $3.9 $4,160 - $7,308	-1,874 Closed	0 $0
Q2 2019 Aug 05, 2019	SELL	$2.75 - $3.7 $1,996 - $2,686	-726 Reduced 27.92%	1,874 $6,000
Q4 2018 Jan 17, 2019	BUY	$1.25 - $2.75 $303 - $668	243 Added 10.31%	2,600 $4,000
Q3 2018 Nov 02, 2018	BUY	$2.23 - $3.82 $3,358 - $5,752	1,506 Added 176.97%	2,357 $0
Q2 2018 Jul 24, 2018	BUY	$2.08 - $4.26 $145 - $298	70 Added 8.96%	851 $0
Q1 2018 May 03, 2018	SELL	$2.32 - $3.44 $306 - $454	-132 Reduced 14.46%	781 $2,000
Q4 2017 Feb 02, 2018	BUY	$3.12 - $4.94 $2,243 - $3,551	719 Added 370.62%	913 $3,000
Q3 2017 Oct 20, 2017	BUY	$3.42 - $4.87 $663 - $944	194	194 $1,000

155

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $716M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.